BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 10, 2009
View Archived Issues
Lundbeck Gains U.S. Foothold in $900M Deal for Ovation
Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today)
Read More
Investors Seeing Positive Side for Biotech in Bleak Economy
Read More
Panel: Keep Options Open to Survive Troubled Times
Read More
ViroPharma Shares Halved as Maribavir Fails Phase III Trial
Read More
Alliance Management Plays Important Role in Avoiding Failure
Read More
Lobbying Dynamics Reveal New Trends in Power
Read More
Gilded Age Can Be Ushered in by Biopartnered Gene Therapies
Read More
Corrections & Clarifications
Read More
Dynavax Soars on Possibility of Regulatory Path for Heplisav
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More